SG301 Injection

DRUG2 trials

Sponsors

Hangzhou Sumgen Biotech Co., Ltd.

Conditions

Antibody Mediated RejectionRelapsed/Refractory Multiple Myeloma

Phase 2

Study of SG301 for Renal AMR After Transplantation

Not yet recruitingNCT07764627

Hangzhou Sumgen Biotech Co., Ltd.Antibody Mediated Rejection

Start: 2026-09-01End: 2028-06-30Target: 10Updated: 2026-08-17

Phase 3

A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients

RecruitingNCT06508983

Hangzhou Sumgen Biotech Co., Ltd.Relapsed/Refractory Multiple Myeloma

Start: 2024-06-14End: 2028-03-31Target: 360Updated: 2026-07-10